2 No-Brainer Growth Stocks to Buy With $100 Right Now

In the ever-evolving landscape of the stock market, identifying growth stocks that can deliver substantial returns is a challenging yet rewarding endeavor. With the S&P 500 index surging about 23% last year, marking the second consecutive year of gains exceeding 20%, the market has shown remarkable resilience. However, the current year has brought its own set of challenges, with tariffs and economic uncertainty putting downward pressure on stocks. Despite these headwinds, there are still opportunities for investors to capitalize on growth stocks that have the potential to deliver significant returns.

One such stock is eli lilly (LLY). Eli Lilly is a drugmaker offering treatments for a variety of conditions, including diabetes, weight loss, plaque psoriasis, anxiety, and fibromyalgia. The company has shown remarkable revenue growth, with a trailing 12-month revenue growth of 27.4% and a 5-year revenue growth outlook of 19.2%. This growth is driven by Mounjaro and Zepbound, two formulations that treat diabetes and obesity, respectively. Both drugs are versions of the compound tirzepatide, a GLP-1 receptor agonist. GLP-1 drugs have gained popularity, with competing products like Ozempic and Wegovy from Novo Nordisk experiencing high demand. Eli Lilly is addressing supply shortages by investing billions in production capacity and has completed clinical trials showing that Zepbound is more effective for weight loss than Wegovy. With an expected EPS growth of 129.7% for this year and a 5-year EPS growth outlook of 41.0%, Eli Lilly is poised for continued growth and is a strong buy for investors looking to capitalize on the biotech sector.

Another growth stock to consider is ServiceNow (NOW). ServiceNow offers a workflow automation platform for enterprise technology management, sold on a subscription basis to Fortune 500 companies and others. The company has shown consistent revenue growth, with a trailing 12-month revenue growth of 23.5% and a 5-year revenue growth outlook of 19.9%. In the third quarter of 2024, ServiceNow had subscription growth of 22.5%, beating the high end of the company's guidance. Customers are responding well to ServiceNow's AI-focused messaging, positioning its Now platform as an essential AI-powered resource for digital transformation. The company's investments in efficiency-enhancing generative AI features are paying off, with industry-targeted AI solutions for financial services, telecommunications, and more. ServiceNow is also incorporating agenic AI into its platform, an emerging AI innovation that can complete complex tasks, learn, and make decisions without human intervention. With an expected EPS growth of 67% for this year and a 5-year EPS growth outlook of 26.8%, ServiceNow is a strong buy for investors looking to capitalize on the tech sector.



In conclusion, Eli Lilly and ServiceNow are two no-brainer growth stocks that investors can buy with $100 right now. Both companies have shown remarkable revenue growth and have strong outlooks for the future. With the current market environment characterized by tariffs and economic uncertainty, investing in growth stocks with strong fundamentals and a proven track record of success is a smart strategy for investors looking to capitalize on the market's potential for growth.

Ask Aime: What are the growth prospects for Eli Lilly and ServiceNow, and how should investors approach their investments?